Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455(7216):1069-75. doi:10.1038/nature07423
Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108-12. doi:10.1038/nature08460
Shao DD, Xue W, Krall EB, et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014;158(1):171-84. doi:10.1016/j.cell.2014.06.004
Cai Y, Hirata A, Nakayama S, et al. CCAAT/enhancer binding protein β is dispensable for development of lung adenocarcinoma. PLoS One. 2015;10(3):e0120647. doi:10.1371/journal.pone.0120647
Niederst MJ, Sequist LV, Poirier JT, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015;6:6377. doi:10.1038/ncomms7377
Chen S, Sanjana NE, Zheng K, et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell. 2015;160(6):1246-60. doi:10.1016/j.cell.2015.02.038
Dumanski JP, Rasi C, Lönn M, et al. Mutagenesis. Smoking is associated with mosaic loss of chromosome Y. Science. 2015;347(6217):81-3. doi:10.1126/science.1262092
Platt RJ, Chen S, Zhou Y, et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell. 2014;159(2):440-55. doi:10.1016/j.cell.2014.09.014
Yao X, Williamson C, Adalsteinsson VA, et al. Tumor cells are dislodged into the pulmonary vein during lobectomy. J Thorac Cardiovasc Surg. 2014;148(6):3224-31.e1. doi:10.1016/j.jtcvs.2014.06.074
Tchaicha JH, Akbay EA, Altabef A, et al. Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC. Cancer Res. 2014;74(17):4676-84. doi:10.1158/0008-5472.CAN-13-3218